Subventions et des contributions :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).

One of the key functions of kidneys is to separate uremic toxins from the blood. Currently, dialysis is the mainx000D
technique of separation of uremic toxins from blood. In this regard, End Stage Renal Disease (ESRD) is ax000D
global health concern with a high prevalence percentage (15% - global; 30% - Canada). The leading treatmentx000D
for ESRD patients is hemodialysis, where the blood is passed through a semipermeable membrane and thex000D
uremic toxins diffuse into the dialysate. This is a repetitive, laborious, time consuming and expensive process.x000D
Qidni Labs Inc., Kitchener, Ontario is developing renal replacement therapies that will eliminate the necessityx000D
of dialysis clinic sessions and will administer continuous and automatic renal therapy. In this proposal Qidnix000D
Labs Inc. and Dr. Praveen Nekkar Rao (Associate Professor, School of Pharmacy, University of Waterloo) arex000D
collaborating to investigate alternative methods of separating uremic toxins using a novel microfluidic platformx000D
and their detection using analytical tools. This proposal aims to investigate novel methods of separating uremicx000D
toxins using a novel microfluidic platform and their detection using analytical tools. The outcomes arex000D
anticipated to reveal the mechanisms of small molecule separation using the microfluidic technology and theirx000D
potential application to kidney patients in Canada thereby providing health and economic benefits tox000D
Canadians.